Gruppo Bianchini
Laboratorio di Medicina Traslazionale (Translational Research Laboratory)
Coordinator Dr. Francesca Bianchini PhD
Brief Biographical sketch of the Coordinator:
Dr Bianchini has expertise in Experimental Pathology, Molecular Biology, Medicinal Chemistry and in vivo Preclinical Models of Cancer. Since graduation in Biological Science, Dr Bianchini has focused her research activity on the role of the interactions between host cells an cancer cells in the tumoral microenvironment that lead to the promotion of neoplastic growth and metastatic diffusion.
Member of the Scientific Board the Doctorate/PhD Program in: Dottorato in Scienze Biomediche
Member of the following Scientific Societies:
SIPMeT: Società Italiana di Patologia e Medicina Traslazionale
SIC: Società Italiana di Cancerologia
Member of editorial board of the following Journals
Research Team
Dr. Gilda La Regina
Dr. Melissa Marchese
Current research interest:
Dr Bianchini developed high level of specialization on the role of integrin receptors in different diseases. Currently, the focus of her research activity includes, but is not limited to:
Development and biological characterization of Arg-Gly-Asp (RGD) integrin antagonist as tools for targeted drug delivery
RGD antagonists as tools for non-invasive medical imaging.
Role of tumor microenvironment factors (pH, pO2, Glucose and Glutamine) in cancer progression.
Nanomedicine and personalized cell-therapy
Key words: Medicinal Chemistry, Preclinical Imaging, Tumor stroma Interactions
Current/recent sources of funding:
RESPONSABILE SCIENTIFICO E ASSEGNATARIO DI FINANZIAMENTO: Sintesi Di Nuovi Agenti Anti-Fibrotici Per Il Trattamento Della Fibrosi Polmonare Idiopatica. 02/08/2019 Fondazione CR Firenze.
RESPONSABILE SCIENTIFICO E ASSEGNATARIO DI FINANZIAMENTO: BANDO DI ATENEO per il finanziamento competitivo di progetti elaborati da Ricercatori a Tempo Determinato dell'Università di Firenze - Anno 2020/2021- co-PI Romina Nassini (RTDb) e Francesca Bianchini (RTDb). Titolo progetto “Cancer-induced bone pain in a murine model of breast carcinoma: role of transient receptor potential channels”.
RESPONSABILE SCIENTIFICO E ASSEGNATARIO DI FINANZIAMENTO: PNRR-CN3 (Centro Nazionale Di Ricerca Sviluppo Di Terapia Genica E Farmaci Con Tecnologia A RNA) Spoke 2 (Cancer): Cross-Talk Stroma-Tumore Nel Microambiente Tumorale Come Target Nelle Terapie Personalizzate Ad RNA.
RESPONSABILE SCIENTIFICO E ASSEGNATARIO DI FINANZIAMENTO: PRIN 2022 - Progetti di Rilevante Interesse Nazionale, Innovative therapeutic interventions against Idiopathic Pulmonary Fibrosis
10 best pubblications of the last 5 years:
Andreucci, E., Bugatti, K., Peppicelli, S., Ruzzolini, J., Lulli, M., Calorini, L., Battistini, L., Zanardi, F., Sartori, A., Bianchini, F. Nintedanib-αVβ6 Integrin Ligand Conjugates Reduce TGFβ-Induced EMT in Human Non-Small Cell Lung Cancer (2023) International Journal of Molecular Sciences, 24 (2), art. no. 1475,
Bugatti, K., Sartori, A., Battistini, L., Ruzzolini, J., Nediani, C., Curti, C., Bianchini, F., Zanardi, F. Nintedanib-αVβ3 Integrin Ligand Dual-Targeting Conjugates towards Precision Treatment of Melanoma (2022) European Journal of Organic Chemistry, 2022 (45), art. no. e202200765, Cited 1 time.
Bugatti, K., Andreucci, E., Monaco, N., Battistini, L., Peppicelli, S., Ruzzolini, J., Curti, C., Zanardi, F., Bianchini, F., Sartori, A. Nintedanib-Containing Dual Conjugates Targeting αVβ6Integrin and Tyrosine Kinase Receptors as Potential Antifibrotic Agents (2022) ACS Omega, 7 (21), pp. 17658-17669. Cited 5 times.
Chatzisideri, T., Leonidis, G., Karampelas, T., Skavatsou, E., Velentza-Almpani, A., Bianchini, F., Tamvakopoulos, C., Sarli, V. Integrin-Mediated Targeted Cancer Therapy Using c(RGDyK)-Based Conjugates of Gemcitabine (2022) Journal of Medicinal Chemistry, 65 (1), pp. 271-284. Cited 4 times.
Sartori, A., Bugatti, K., Portioli, E., Baiula, M., Casamassima, I., Bruno, A., Bianchini, F., Curti, C., Zanardi, F., Battistini, L. New 4-aminoproline-based small molecule cyclopeptidomimetics as potential modulators of α4β1 integrin (2021) Molecules, 26 (19), art. no. 6066. Cited 2 times.
Ruzzolini, J., Chioccioli, S., Monaco, N., Peppicelli, S., Andreucci, E., Urciuoli, S., Romani, A., Luceri, C., Tortora, K., Calorini, L., Caderni, G., Nediani, C., Bianchini, F. Oleuropein-rich leaf extract as a broad inhibitor of tumour and macrophage iNOS in an apc mutant rat model (2021) Antioxidants, 10 (10), art. no. 1577, . Cited 13 times.
Chatzisideri, T., Dalezis, P., Leonidis, G., Bousis, S., Trafalis, D., Bianchini, F., Sarli, V. Synthesis and biological studies of c(RGDyK) conjugates of cucurbitacins (2021) Future Medicinal Chemistry, 13 (10), pp. 877-895. Cited 5 times.
Peppicelli, S., Andreucci, E., Ruzzolini, J., Bianchini, F., Calorini, L. FDG uptake in cancer: A continuing debate (2020) Theranostics, 10 (7), pp. 2944-2948. Cited 17 times.
Bianchini, F., De Santis, A., Portioli, E., Russo Krauss, I., Battistini, L., Curti, C., Peppicelli, S., Calorini, L., D'Errico, G., Zanardi, F., Sartori, A. Integrin-targeted AmpRGD sunitinib liposomes as integrated antiangiogenic tools (2019) Nanomedicine: Nanotechnology, Biology, and Medicine, 18, pp. 135-145. Cited 21 times.
Bianchini, F., Portioli, E., Ferlenghi, F., Vacondio, F., Andreucci, E., Biagioni, A., Ruzzolini, J., Peppicelli, S., Lulli, M., Calorini, L., Battistini, L., Zanardi, F., Sartori, A. Cell-targeted c(AmpRGD)-sunitinib molecular conjugates impair tumor growth of melanoma (2019) Cancer Letters, 446, pp. 25-37. Cited 29 times.
Previous research experiences:
Prof. Charles N. Serhan at the Brigham&Women’s Hospital, Harvard Medical School, Boston (MA) US. Role of lipid mediators, derived from the omega-6 and omega-3 poly-unsaturated fatty acids, in the regulation of inflammatory response and resolution of inflammation.
Collaborations:
Prof.ssa Franca Zanardi, Università di Parma – Dipartimento di Scienze degli Alimenti e del Farmaco
Prof. Andrea Sartori, Università di Parma– Dipartimento di Scienze degli Alimenti e del Farmaco
Prof. Andrea Trabocchi, Università di Firenze – Dipartimento di Chimica
Prof. Roberto Fiammengo, Università di Verona – Dipartimento di Biotecnologie
Prof.ssa Vasiliki Sarli, Aristotle University of Thessaloniki, Chemistry Department.
Dipartimenti aderenti oltre al DSBSC UNIFI:
CIRIB, Centro Interdipartimentale di Ricerca in Imaging Biomedico
Ultimo aggiornamento
08.01.2024